Skip Navigation


ToxSci Advance Access originally published online on March 23, 2005
Toxicological Sciences 2005 85(2):1024-1032; doi:10.1093/toxsci/kfi159
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
85/2/1024    most recent
kfi159v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Foster, P. M. D.
Right arrow Articles by Harris, M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Foster, P. M. D.
Right arrow Articles by Harris, M. W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences vol. 85 no. 2 © The Author 2005. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Changes in Androgen-Mediated Reproductive Development in Male Rat Offspring Following Exposure to a Single Oral Dose of Flutamide at Different Gestational Ages

Paul M. D. Foster1 and Martha W. Harris

Laboratory of Molecular Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709

Received February 15, 2005; accepted March 17, 2005

Previous studies have indicated that the androgen receptor antagonist, flutamide, can produce a suite of reproductive malformations in the male rat when orally administered daily on gestation days (GD) 12–21. The objective of this study was to investigate the gestation time dependence for the induction of these malformations to establish a robust animal model for future studies of gene expression related to specific malformations. Groups of timed-pregnant Sprague-Dawley rats (GD 0 = day of mating) were administered flutamide as a single gavage dose (50 mg/kg) on GD 16, 17, 18, or 19 with 10 dams per group. Control animals (5 dams per time per group) were administered corn oil vehicle (2 ml/kg). Dams were allowed to litter, and their adult male offspring were killed at postnatal day (PND) 100 ± 10. Anogenital distance was measured at PND 1 and 100. Areolae were scored at PND 13, and permanent nipples evaluated at PND 100. No reproductive tract malformations were found in control male offspring. In the treated groups, malformations were noted following exposure at every GD, although the incidence of specific malformations varied by GD. At GD 16, the highest incidence was noted for permanent nipples (46% pups, 60% litters), epispadias (12% pups, 30% litters), and missing epididymal components (5% pups, 20% litters). The highest incidences for hypospadias (58% pups, 80% litters), vaginal pouch (49% pups, 70% litters), cleft prepuce (29% pups, 60% litters), and missing prostate lobes (12% pups, 60% litters) were noted at GD 17. At GD 18 the highest incidence of malformations noted were epispadias (5% pups, 30% litters), reduced prostate size (32% pups, 90% litters), and abnormal kidneys (3% pups, 30% litters) and bladders (7% pups, 30% litters), while on GD 19 70% of the litters had animals with abnormal seminal vesicles. Testicular and epididymal morphological changes were noted at all GDs and were consistent with the gross observations and peaked in incidence and severity on GD17. The major discrepancy between this study and previous multiple-dose studies was in the very few numbers of animals presenting with cryptorchidism (only one each on GDs 16 and 17), suggesting that exposure over multiple days may be required to induce this malformation. Thus, a single gestational exposure of flutamide induced numerous reproductive tract malformations consistent with previously reports following multiple exposures, with the timing of the exposure producing marked tissue selectivity in the response noted in adult offspring.

Key Words: flutamide; gestational exposure; endocrine; disruptor; antiandiogen.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
T. Saloniemi, T. Lamminen, K. Huhtinen, M. Welsh, P. Saunders, H. Kujari, and M. Poutanen
Activation of Androgens by Hydroxysteroid (17{beta}) Dehydrogenase 1 in Vivo as a Cause of Prenatal Masculinization and Ovarian Benign Serous Cystadenomas
Mol. Endocrinol., November 1, 2007; 21(11): 2627 - 2636.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
H O Goyal, T D Braden, C S Williams, and J W Williams
Role of estrogen in induction of penile dysmorphogenesis: a review
Reproduction, August 1, 2007; 134(2): 199 - 208.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Welsh, P. T. K. Saunders, and R. M. Sharpe
The Critical Time Window for Androgen-Dependent Development of the Wolffian Duct in the Rat
Endocrinology, July 1, 2007; 148(7): 3185 - 3195.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
H O Goyal, T D Braden, P S Cooke, M A Szewczykowski, C S Williams, P Dalvi, and J W Williams
Estrogen receptor-{alpha} mediates estrogen-inducible abnormalities in the developing penis
Reproduction, May 1, 2007; 133(5): 1057 - 1067.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Welsh, P. T. K. Saunders, N. I. Marchetti, and R. M. Sharpe
Androgen-Dependent Mechanisms of Wolffian Duct Development and Their Perturbation by Flutamide
Endocrinology, October 1, 2006; 147(10): 4820 - 4830.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R. Pasquali and A. Gambineri
Insulin-sensitizing agents in polycystic ovary syndrome.
Eur. J. Endocrinol., June 1, 2006; 154(6): 763 - 775.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.